PriceTargets.com logo

Molecular Partners - MOLN Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 222.06%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$3.73 As of 05/1/2025 11:31 AM ET
▼ -0.044 (-1.17%)

This chart shows the closing price for MOLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$3.90Closing price on 04/30/25:
Get New Molecular Partners Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOLN

Analyst Price Target is $12.00
▲ +222.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Molecular Partners in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 222.06% upside from the last price of $3.73.

This chart shows the closing price for MOLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$2.48$4.89$7.29$9.70$12Closing price on 04/30/25: $3.90High$12.00Average$12.00Low$12.00




Current Consensus is Strong Buy

The current consensus among 2 contributing investment analysts is to buy (strong buy) stock in Molecular Partners. This rating has held steady since December 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/11/2025Lifesci CapitalInitiated CoverageOutperform$12.00
10/7/2024Leerink PartnrsUpgradeStrong-Buy
12/5/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$6.60 ➝ $4.50
8/30/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
8/29/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$30.00 ➝ $8.00
5/25/2022Credit Suisse GroupUpgradeUnderperform ➝ Neutral
4/28/2022Leerink PartnersLower Target$42.00 ➝ $29.00
4/27/2022Kempen & CoDowngradeBuy ➝ Neutral
4/27/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform
3/18/2022JPMorgan Chase & Co.Lower TargetCHF 22 ➝ CHF 21
1/14/2022Credit Suisse GroupBoost TargetCHF 17 ➝ CHF 23
1/14/2022Leerink PartnersBoost TargetOutperform$35.00 ➝ $42.00
12/16/2021Leerink PartnersReiterated RatingBuy
8/27/2021Leerink PartnersLower TargetOutperform$36.00 ➝ $35.00
8/10/2021Credit Suisse GroupReiterated RatingNeutral
8/9/2021HC WainwrightReiterated RatingBuy$25.00
7/12/2021Leerink PartnersReiterated RatingOutperform
7/12/2021CowenInitiated CoverageOutperform
7/12/2021Royal Bank of CanadaSet TargetOutperform$19.52
6/21/2021HC WainwrightReiterated RatingBuy$25.00
(Data available from 5/1/2020 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/31/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/1/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2025

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Molecular Partners logo
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Read More

Today's Range

Now: $3.73
Low: $3.80
High: $3.96

50 Day Range

MA: $4.15
Low: $3.54
High: $5.03

52 Week Range

Now: $3.73
Low: $3.36
High: $12.70

Volume

11,656 shs

Average Volume

20,982 shs

Market Capitalization

$150.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Molecular Partners?

The following Wall Street sell-side analysts have issued reports on Molecular Partners in the last twelve months: Leerink Partnrs, and Lifesci Capital.
View the latest analyst ratings for MOLN.

What is the current price target for Molecular Partners?

0 Wall Street analysts have set twelve-month price targets for Molecular Partners in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 222.1%. Lifesci Capital has the highest price target set, predicting MOLN will reach $12.00 in the next twelve months. Lifesci Capital has the lowest price target set, forecasting a price of $12.00 for Molecular Partners in the next year.
View the latest price targets for MOLN.

What is the current consensus analyst rating for Molecular Partners?

Molecular Partners currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for MOLN.

What other companies compete with Molecular Partners?

Other companies that are similar to Molecular Partners include AnaptysBio, KalVista Pharmaceuticals, Arbutus Biopharma, Trevi Therapeutics and AbCellera Biologics. Learn More about companies similar to Molecular Partners.

How do I contact Molecular Partners' investor relations team?

The company's listed phone number is 41-44-755-7700 and its investor relations email address is seth.lewis@molecularpartners.com. The official website for Molecular Partners is www.molecularpartners.com. Learn More about contacing Molecular Partners investor relations.